Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray

Journal of Orthopaedic Research

Volumn 34, Issue 9, 2016, Pages 1606-1612

  Gao, Yan ^a,b   Liao, Yunfei ^a   Shen, Jacson K ^a   Feng, Yong ^a   Choy, Edwin ^a   Cote, Gregory ^a   Harmon, David ^a   Mankin, Henry J ^a   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

metastasis; osteosarcoma; P glycoprotein (Pgp); prognosis; tissue microarray (TMA)

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL MEMBRANE; CHILD; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH THROUGHPUT TISSUE MICROARRAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR NECROSIS;

EID: 84984633412     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.23173     Document Type: Article

References (35)

1. Ottaviani G, Jaffe N. 2009. The epidemiology of osteosarcoma. Cancer Treat Res 152:3–13.
2. Chou AJ, Geller DS, Gorlick R. 2008. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10:315–327.
3. Osborne TS, Khanna C. 2012. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol 146:132–142.
4. Hattinger CM, Pasello M, Ferrari S, et al. 2010. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15:615–634.
5. Geller DS, Gorlick R. 2010. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8:705–718.
6. Meyers PA. 2009. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 9:1035–1049.
7. Dieudonne FX, Marion A, Hay E, et al. 2010. High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res 70:5399–5408.
8. Gillet JP, Gottesman MM. 2010. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47–76.
9. Chou AJ, Gorlick R. 2006. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6:1075–1085.
10. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.
11. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. 1995. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380–1385.
12. Chan HS, Grogan TM, Haddad G, et al. 1997. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89:1706–1715.
13. Schwartz CL, Gorlick R, Teot L, et al. 2007. Multiple drug resistance in osteogenic sarcoma: INT0133 from the children's oncology group. J Clin Oncol 25:2057–2062.
14. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. 2003. P-glycoprotein: from genomics to mechanism. Oncogene 22:7468–7485.
15. Chan HS, Thorner PS, Haddad G, et al. 1990. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689–704.
16. Yamamoto O, Wada T, Takahashi M, et al. 2000. Prognostic value of P-glycoprotein expression in bone and soft-tissue sarcoma. Int J Clin Oncol 5:164–170.
17. Wunder JS, Bull SB, Aneliunas V, et al. 2000. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18:2685–2694.
18. Kononen J, Bubendorf L, Kallioniemi A, et al. 1998. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847.
19. Khouja MH, Baekelandt M, Sarab A, et al. 2010. Limitations of tissue microarrays compared with whole tissue sections in survival analysis. Oncol Lett 1:827–831.
20. Kyndi M, Sorensen FB, Knudsen H, et al. 2008. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 47:591–599.
21. Rubin MA, Dunn R, Strawderman M, et al. 2002. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312–319.
22. Sabile AA, Arlt MJ, Muff R, et al. 2013. Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice. Biochim Biophys Acta 1832:1173–1182.
23. Jentzsch T, Robl B, Husmann M, et al. 2014. Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray. Anticancer Res 34:3881–3889.
24. Salas S, Jiguet-Jiglaire C, Campion L, et al. 2014. Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma. BMC Cancer 14:606.
25. Ferrari S, Bertoni F, Zanella L, et al. 2004. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 100:1936–1942.
26. Hennequin E, Delvincourt C, Pourny C, et al. 1993. Expression of mdr1 gene in human breast primary tumors and metastases. Breast Cancer Res Treat 26:267–274.
27. Weinstein RS, Jakate SM, Dominguez JM, et al. 1991. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51:2720–2726.
28. Zorzos HS, Lazaris AC, Korkolopoulou PA, et al. 2003. Multidrug resistance proteins and topoisomerase IIalpha expression in colon cancer: association with metastatic potential. Pathology 35:315–318.
29. Meyers PA, Gorlick R. 1997. Osteosarcoma. Pediatr Clin North Am 44:973–989.
30. Miwa S, Takeuchi A, Ikeda H, et al. 2013. Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft. PLoS ONE 8:e71362.
31. Jawad MU, Cheung MC, Clarke J, et al. 2011. Osteosarcoma: improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol 137:597–607.
32. Chan HS, Haddad G, DeBoer G, et al. 1997. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89:1706–1715.
33. Bacci G, Longhi A, Versari M, et al. 2006. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154–1161.
34. Meyers PA, Gorlick R, Heller G, et al. 1998. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16:2452–2458.
35. Meyers PA, Schwartz CL, railo KM, et al. 2005. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011.